Generic Medicine Info
Indications and Dosage
Prophylaxis of surgical infections
Adult: 2 g as slow inj over 3-5 min or by intermittent or continuous infusion 30-60 min prior to surgery, followed by 2 g during surgery, then 2 g 6 hrly after surgery for 24 hr; continued for up to 72 hr for patients undergoing heart valve replacement or arthroplasty.

Susceptible infections
Adult: 0.5-1 g 4-6 hrly by slow IV inj over 3-5 min or by intermittent or continuous infusion, deep IM inj. Max: 12 g daily.
Child: 80-160 mg/kg daily in divided doses, by deep IM inj, slow IV inj, or by intermittent or continuous IV infusion.
Renal Impairment
Max dose should be given after IV loading dose of 1-2 g according to CrCl.
CrCl (mL/min) Dosage
<2 500 mg 8 hrly.
2-10 500 mg 6 hrly.
11-25 1 g 6 hrly.
26-50 1.5 g 6 hrly.
51-80 2 g 6 hrly.
IM: Dissolve cefalotin 1 g in sterile water for inj 4 mL; may add a small amount of diluents (e.g. 0.2-0.4 mL) if the soln do not dissolve completely. IV: Dissolve cefalotin 1 g in saline 10 mL or glucose soln 5%.
Hypersensitivity to cephalosporins.
Special Precautions
Hypersensitivity to penicillins. History of allergy. Renal impairment. Pregnancy and lactation.
Adverse Reactions
Hypersensitivity reactions (e.g. skin rashes, urticaria, eosinophilia, fever, serum sickness-like reactions); neutropenia, thrombocytopenia, bleeding complications related to hypoprothrombinaemia and/or platelet dysfunction, nephrotoxicity, acute renal tubular necrosis, acute interstitial nephritis, transient increase in liver enzyme values, convulsions and other signs of CNS toxicity, thrombophlebitis (IV) and pain (IM) at inj site. Rarely, haemolytic anaemia, agranulocytosis, hepatitis, cholestatic jaundice, GI effects (e.g. nausea, vomiting, diarrhoea).
Potentially Fatal: Anaphylaxis, pseudomembranous colitis.
Monitoring Parameters
Monitor renal and haematological status esp during prolonged and high dose therapy.
Drug Interactions
Increased risk of nephrotoxicity w/ aminoglycosides (e.g. gentamicin, tobramycin) and loop diuretics (e.g. furosemide). Antagonistic effect w/ bacteriostatic antibacterials. Probenecid may inhibit renal excretion of cefalotin.
Lab Interference
May interfere w/ Jaffe method of measuring creatinine concentrations and may produce falsely high values. Positive response to direct Coombs' test. False-positive reactions for glucose using copper-reduction reactions.
Description: Cefalotin interferes w/ bacterial cell wall peptidoglycan synthesis by binding to penicillin-binding proteins, eventually leading to cell lysis and death. It has bactericidal action.
Absorption: Poorly absorbed from the GI tract. Time to peak plasma concentration: W/in 30 min (IM); 15 min (IV).
Distribution: Widely distributed in body tissues and fluids except the brain and CSF (low and unpredictable concentrations). Crosses the placenta and enters breast milk (low concentrations). Plasma protein binding: Approx 70%.
Metabolism: Hepatic via deacetylation.
Excretion: Via urine (approx 60-70%) and bile (very small amount). Plasma half-life: Approx 30-50 min.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Cephalothin, CID=6024, https://pubchem.ncbi.nlm.nih.gov/compound/Cephalothin (accessed on Jan. 21, 2020)

Store below 25°C. Protect from direct sunlight.
MIMS Class
Buckingham R (ed). Cefalotin Sodium. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/10/2014.

Disclaimer: This information is independently developed by MIMS based on Cefalotin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in